Non-profit website: free to use. No fees from patients, hospitals or doctors. Not an agency. · Free · Not an agencyAbout this site
Medical oncology · Sun Yat-sen University Cancer Center · Guangzhou

Dr. Chen Mingyuan陈明远

Chief Physician · Professor

Summary compiled from public information, updated 18 Nov 2026. It has not been checked against the hospital website yet. Confirm details with the hospital before you travel.

Dr. Chen Mingyuan

Professional overview

Chief Physician and Professor specializing in multidisciplinary comprehensive treatment and translational research of nasopharyngeal carcinoma at Sun Yat-sen University Cancer Center.

SpecialtyMedical oncology
Clinical titleChief Physician
Academic rolesProfessor, Doctoral Supervisor
DepartmentNasopharyngeal Department
HospitalSun Yat-sen University Cancer Center
CityGuangzhou

Areas of focus

Nasopharyngeal carcinomaSpecializes in radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy for nasopharyngeal carcinoma, and their clinical translational research.

Background

  • 2010Led the National Natural Science Foundation project 'Molecular Mechanism of Hypoxia-Inducible Factor HIF-1α Downregulating Transcription Factor TELB to Promote Nasopharyngeal Carcinoma Metastasis' (Jan 2010–Dec 2012).
  • 2013Led the Sun Yat-sen University Clinical Medicine 5010 Program 'Multicenter Randomized Controlled Trial Comparing Primary Site Radiotherapy Plus Systemic Chemotherapy Versus Systemic Chemotherapy Alone for Chemotherapy-Sensitive Newly Diagnosed Distant Metastatic Nasopharyngeal Carcinoma' (Jan 2013–Jul 2023).
  • 2013Awarded Ministry of Education 'New Century Excellent Talents Support Program' (Jan 2013–Dec 2015).
  • 2014Led the Guangdong Provincial Key Project 'Clinical Study on Prognostic Prediction Model Guiding Induction Chemotherapy for Nasopharyngeal Carcinoma Based on Exosomal Metastasis-Related Protein Biomarkers' (Jan 2015–Dec 2017).
  • 2015Led the Sun Yat-sen University Cancer Center Special Support Project 'Comprehensive Treatment and Translational Research of Recurrent/Metastatic Nasopharyngeal Carcinoma' (Sep 2015–Sep 2018).
  • 2016Led the Guangzhou Municipal Key Industry Collaborative Innovation Project 'Multicenter Randomized Controlled Trial of Induction Chemotherapy Combined with Concurrent Chemoradiotherapy for Highly Metastatic Nasopharyngeal Carcinoma' (Apr 2016–Apr 2019).
  • 2017Led the Guangdong Provincial Key Project 'Establishment and Clinical Application of Multi-Omics Data Integration Technology System for Nasopharyngeal Carcinoma' (Jan 2017–Dec 2019).
  • 2019Awarded National High-Level Talent Program 'Innovative Leading Talent in Science and Technology' (Sep 2019–Jul 2024).
  • 2020Led the Guangdong Provincial Precision Medicine and Stem Cell Major Special Project 'Development and Application of Clinical Decision Support System for Precision Oncology' (Apr 2020–Apr 2023).
  • 2021Published the monograph Nasopharyngeal Minimally Invasive Surgery (Guangdong Science and Technology Press).
  • 2021Led a prospective clinical study on early screening and diagnosis of nasopharyngeal carcinoma (Jiangxi Provincial Technological Innovation Guidance Project, Aug 2021–Aug 2024).
  • 2022Published the monograph Nasopharyngeal Carcinoma Diagnosis and Treatment Guidelines Handbook (People's Medical Publishing House).

Experience & recognition

  • Published over 100 SCI papers, including more than 50 as corresponding, first, or co-first author.
  • Published 7 papers with impact factor >20, 24 papers with impact factor 10–20; highest impact factor: 41.3.
  • Published in journals including The Lancet Oncology and JAMA Oncology.
  • Results adopted by 5 domestic and international treatment guidelines.
  • Received over RMB 40 million in research funding.
  • Authored 2 monographs.
  • Holds 10 authorized invention patents.
  • Awarded Guangdong Medical Science Award Second Prize (sole recipient, 2019).

Professional roles

  • Vice Chair and Secretary-General, Nasopharyngeal Carcinoma Prevention and Treatment Society, China International Exchange and Promotive Association for Medical and Health Care (CPAM)
  • Vice Chair, Nasopharyngeal Carcinoma Professional Committee, Chinese Society of Human Health Science and Technology Promotion
  • Chair, Nasopharyngeal Carcinoma Specialty Committee, Guangdong Anti-Cancer Association
  • Member, Nasopharyngeal Carcinoma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
  • Executive Deputy Director, Nasopharyngeal Department, Sun Yat-sen University Cancer Center
  • Director, Minimally Invasive Surgery Specialty for Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
  • Director, Nasopharyngeal Carcinoma Surgical Cooperative Ward, Sun Yat-sen University Cancer Center–Guangzhou Medical University Affiliated Fifth Hospital

Frequently asked questions

What does Dr. Chen Mingyuan specialize in?

Specializes in radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy for nasopharyngeal carcinoma, and their clinical translational research.

Which hospital and department is Dr. Chen Mingyuan in?

Nasopharyngeal Department at Sun Yat-sen University Cancer Center

Sources

Dr. Chen Mingyuan has not reviewed this page.